Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945361 | 0.86 | POLB (0.37) | MMP9MMP8MMP14EPHX1MAPT | |
| SCHEMBL21104481 | 0.82 | TSHR (0.44) | TSHRPOLB | |
| SCHEMBL24673629 | 0.80 | MEN1 (0.41) | MMP9MMP8MMP14EPHX1MAPT | |
| SCHEMBL25727664 | 0.77 | POLB (0.39) | EPHX1MAPTTSHRPOLBCA2 | |
| SCHEMBL19996869 | 0.77 | EPHX1 (0.50) | EPHX1MAPTPOLBDPP7CA2 | |
| SCHEMBL24451143 | 0.76 | POLB (0.45) | EPHX1MAPTTSHRPOLBCA2 | |
| SCHEMBL23602777 | 0.76 | MAPT (0.45) | MMP9MMP8MMP14MAPTHSD17B10 | |
| SCHEMBL25477841 | 0.75 | MAPT (0.41) | MMP9MMP8MMP14EPHX1MAPT | |
| SCHEMBL19996832 | 0.74 | ACE2 (0.50) | EPHX1MAPTCA2ACE2 | |
| SCHEMBL26280158 | 0.74 | SMN1; SMN2 (0.46) | EPHX1MAPTHSD17B10TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MMP9 899/4885MMP8 901/4885MMP14 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.